- Home
- VTVT vs MAIA Comparison
VTVT vs MAIA Comparison
Compare VTVT & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTVT
- MAIA
- Stock Information
- Founded
- VTVT 2015
- MAIA 2018
- Country
- VTVT United States
- MAIA United States
- Employees
- VTVT N/A
- MAIA N/A
- Industry
- VTVT Biotechnology: Pharmaceutical Preparations
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- VTVT Health Care
- MAIA Health Care
- Exchange
- VTVT Nasdaq
- MAIA Nasdaq
- Market Cap
- VTVT 56.7M
- MAIA 46.7M
- IPO Year
- VTVT 2015
- MAIA 2022
- Fundamental
- Price
- VTVT $14.64
- MAIA $1.82
- Analyst Decision
- VTVT Strong Buy
- MAIA
- Analyst Count
- VTVT 2
- MAIA 0
- Target Price
- VTVT $35.50
- MAIA N/A
- AVG Volume (30 Days)
- VTVT 7.9K
- MAIA 549.7K
- Earning Date
- VTVT 08-07-2025
- MAIA 08-08-2025
- Dividend Yield
- VTVT N/A
- MAIA N/A
- EPS Growth
- VTVT N/A
- MAIA N/A
- EPS
- VTVT N/A
- MAIA N/A
- Revenue
- VTVT $17,000.00
- MAIA N/A
- Revenue This Year
- VTVT N/A
- MAIA N/A
- Revenue Next Year
- VTVT N/A
- MAIA N/A
- P/E Ratio
- VTVT N/A
- MAIA N/A
- Revenue Growth
- VTVT N/A
- MAIA N/A
- 52 Week Low
- VTVT $12.12
- MAIA $1.40
- 52 Week High
- VTVT $26.99
- MAIA $4.24
- Technical
- Relative Strength Index (RSI)
- VTVT 40.96
- MAIA 53.36
- Support Level
- VTVT $14.53
- MAIA $1.60
- Resistance Level
- VTVT $16.76
- MAIA $2.03
- Average True Range (ATR)
- VTVT 0.62
- MAIA 0.12
- MACD
- VTVT 0.04
- MAIA 0.02
- Stochastic Oscillator
- VTVT 25.11
- MAIA 58.14
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Its product pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.